FDA Switch Strategy May Need Retooling To Handle Chronic Drugs
This article was originally published in The Tan Sheet
Executive Summary
The ongoing OTC statins debate highlights a need for FDA advisors to consider the societal impact of a drug therapy when evaluating Rx-to-OTC switch candidates, according to NDAC Chair Alastair Wood
You may also be interested in...
Mevacor Daily Regimen Compliance Questioned By FDA Committees
A joint FDA advisory committee review of J&J/Merck's nonprescription Mevacor Daily centered in part on long-term consumer compliance with the indicated cholesterol-lowering regimen
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.